This approach can be expanded to other cancer types with PET tracers beyond FDG, such as prostate-specific membrane antigen (PSMA), fibroblast activation protein inhibitor (FAPI), Fluoroestradiol (FES), Fluorothymidine (FLT), and many others. Here, FOLH1 is linked to cancer.